The European Rare Diseases Research Alliance (ERDERA) is pleased to announce the upcoming launch of the ERDERA Clinical Trial Call 2026 (ECTC), expected to open on 1 July 2026.
The ECTC aims to support multinational, GCP-compliant Phase I, Phase I/II and Phase II interventional clinical trials in rare diseases, generating robust clinical evidence and, where appropriate, data of regulatory relevance to support future interactions with regulatory authorities and subsequent clinical development.
For the ERDERA Clinical Trial Call all funding is provided centrally from the European Commission contribution to ERDERA and is administered and distributed by Fondazione Telethon (FTELE). There is a single set of funding rules applicable to all participants, regardless of their country of origin. No parallel national submissions are required.
Priority Areas (not eligibility criteria):
- paediatric rare diseases;
- rapidly progressive rare diseases;
- and rare diseases with no approved therapeutic options or with substantial residual unmet medical need despite existing treatments.
Eligible Countries:
Austria, Belgium, Bulgaria, Canada, Cyprus, Czech Republic, Denmark, Estonia, France, Germany, Hungary, Ireland, Israel, Italy, Latvia, Lithuania, Luxembourg, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden, The Netherlands, Türkiye and the United Kingdom.
Please note that, in accordance with the current draft call provisions, the Clinical Trial Sponsor must be established in an EU Member State or Norway.
Eligible Applicants:
• Universities, higher education institutions and research institutes;
• Hospitals and clinical centres;
• Non-profit research organisations and foundations;
• Patient Advocacy Organisations (PAOs);
• Small and Medium Enterprises (SMEs), subject to the specific funding provisions applicable under the Call. • Small and Medium Enterprises (SMEs), subject to the specific funding provisions applicable under the Call.
Each consortium must designate:
• A Clinical Trial Sponsor;
• A Coordinating Investigator;
• At least one patient partner represented by a PAO or other organised patient group;
• Access to a qualified multinational Clinical Trial Management Organisation (CTMO).
Indicative Application Process:
• Stage 0 – Expression of Interest (EOI): 1 July – 10 September 2026
• Stage 1 – Short Proposal Stage: 15 September – 29 October 2026
• Stage 2 – Support Stage: January – July 2027
• Stage 3 – Full Proposal Stage: July – September 2027
• Stage 4 – Initial Trial Execution
• Stage 5 – Conditional Continuation Funding
Funding Decisions: February 2028
An information webinar for prospective applicants will be held on 6 July 2026 (15:00–17:00 CEST) and will provide an overview of the call objectives, eligibility requirements, evaluation process and indicative timeline.More information and registration here.
More information about the upcoming call is available at the following links:
https://erdera.org/call/ctc2026
https://erdera.org/news/erdera-clinical-trial-call-2026-pre-announcement-and-key-dates
ERDERA Clinical Trial Call 2026 – Information Webinar – ERDERA
For scientific questions, please contact the scientific secretariat of the call for clinical trials: Contact-Scientific Secretariat ERDERA Clinical Trial Call: ctc.secretariat@erdera.org
DOCUMENTS
ERDERA_Clinical_Trial_Call_Text_Draft
ERDERA_Clinical_Trial_Call_Pre-Announcement
CONTACT PERSON
Katarína Bibová
T: 02/ 57510 136